The ␤-adrenergic blockers and antagonists of the renin-angiotensin system (RAS) are among the drugs that present better results in the control of cardio-metabolic diseases. The aim of the present study was to evaluate the effect of the association of the ␤-blocker, atenolol, and an oral formulation of Ang-(1-7) on lipid metabolism in spontaneously hypertensive rats (SHR). The main results showed that SHR treated with oral formulation of Ang-(1-7) in combination to atenolol have an improvement of lipid metabolism with a reduction of total plasma cholesterol, improvement of oral fat load tolerance and an increase in the lipolytic response stimulated by the ␤-adrenergic agonist, isoproterenol, without modification of resting glucose or insulin sensitivity in adipocytes. In conclusion, we showed that administration of an Ang-(1-7) oral formulation in association with a ␤-blocker induces beneficial effects on dyslipidemia treatment associated with hypertension.
Introduction
Dyslipidemia is well recognized as one of the most pernicious metabolic disorders, consisting in an important risk factor of cardiovascular disease, the most prevalent worldwide [5, 11] . Studies have shown a potential role for antihypertensive drugs on lipid regulation [15] . ␤-Adrenergic blockers and antagonists of the reninangiotensin system (RAS) are among the drugs that present better results in the control of metabolic syndrome and dyslipidemia [4, 15, 25, 27, 29] .
Recent studies point out for a role of ACE2/Angiotensin-(1-7)/Mas axis as an important counterregulatory arm of the RAS, opposing several angiotensin (Ang) II actions in obesity [17, 20, 21] . Transgenic animals that present a life time increase in plasma Ang-(1-7) showed an improved lipid and glucose metabolism indicating an important metabolic effect for Ang-(1-7) [20] . On the other hand, mice that lack the Ang-(1-7) receptor, Mas [21] , present a metabolic-like syndrome [21] .
␤-Blockers were also shown to present direct action on metabolic tissues such as muscle, liver and adipose tissue [10, 18, 26] , inhibiting hormone-sensitive lipase activity in the early weeks of treatment and modulating cholesterol biosynthesis and/or catabolism [26] . In this context, the aim of the present study was to evaluate the effect of the association of a ␤-blocker, atenolol, and an oral formulation of Ang-(1-7) [12] on lipid metabolism in spontaneously hypertensive rats (SHR).
Materials and methods

Animals
Experiments were performed in male SHR (20 ± 2 weeks old) obtained from the animal facilities Biological Science Institute (CEBIO, UFMG, Belo Horizonte, MG, Brazil) kept in 12 h light/dark cycle room.
Treatment
Four group of animals received orogastric gavage (1 mL/kg, daily) for 14 weeks of: (a) Ang-(1-7)/hydroxypropyl-␤-cyclodextrin [CD-Ang-(1-7), 30 g/kg/day of the peptide; n = 8]; (b) ␤-blocker (atenolol, 3 mg/kg/day; n = 8); (c) the association of CD-Ang-(1-7) and atenolol (n = 9) at same doses; and (d) vehicle, hydroxypropyl-␤-cyclodextrin (CD, 50 g/kg/day; n = 9). The proportion of Ang-(1-7) and hydroxypropyl-␤-cyclodextrin in the oral formulation was 43% and 57%, respectively. Blood pressure was measured in a group of animals by telemetry for 8 weeks, as previously described [3] .
Lipid profile
After 14 weeks of treatment, total serum cholesterol and triglycerides were measured by enzymatic method (Kit KATAL Biotecnológica Ind. Com. Ltd., Brazil) in fasted animals. In addition, oral fat tolerance was evaluated by the changes in serum triglycerides 60, 120, and 210 min after oral administration of a fat load (10 mL/kg), as described by Mori et al. [14] .
Lipolysis
Lipolysis was measured by the rate of glycerol released from adipocytes. To isolate adipocytes, the fat pads of epididymus were digested with collagenase at 37 • C in a shaking water bath for 45 min. Next, cells were filtered through nylon mesh and washed three times with a HEPES buffer (pH 7.4) containing: 137 mM NaCl, 5 mM KCl, 4.2 mM NaHCO 3 , 1.3 mM CaCl 2 , 0.5 mM MgCl 2 , 0.5 mM MgSO 4 , 0.5 mM KH 2 PO 4 , 20 mM HEPES and 1% BSA. After a period of incubation, an aliquot of the infranatant was removed for enzymatic determination of glycerol released into the medium. Glycerol levels were measured before and after isoproterenol (0.1 mol/L) or isoproterenol followed by insulin (12.5 ng/mL) incubation.
Fasting glucose
At eighth week of treatment, fasting glucose was evaluated in tail blood sample using an Accu-Check glucometer (Roche Diagnostics, Indianapolis, IN).
Glucose uptake
Glucose uptake was also measured in isolated adipocytes from epididymal fat tissue. The isolated adipocytes were incubated for 45 min at 37 • C in the presence or absence of insulin (50 ng/mL). The uptake of 2-deoxy-[3H]glucose (2DOG) was used to determine the insulin sensitivity in glucose uptake, as described by Green [7] . The assay was initiated by the addition of 2DOG (0.2 Ci/tube) for 3 min. Next, cells were separated by centrifugation through silicone oil and cell-associated radioactivity was determined by scintillation counting. Nonspecific association of 2DOG was determined by performing parallel incubations in the presence of 15 mmol/l phloretin, and this value was subtracted from glucose transport activity in each condition.
Lipoprotein lipase (LPL) activity
Epididymal fat pads were homogenized in buffer Tris-HCl (pH 8.3) containing detergents. LPL activity was measured using a [9,10-3H]triolein containing substrate with lecithin [16] and 24 h fasted rat plasma as a source of apo CII. The reaction was stopped with a mixture of extraction [1] , and the released 3H-free fatty acids (FFAs) were quantified by liquid scintillation. The enzyme activity was expressed as nanomoles of FFA released per minute. § p < 0.05 in comparison to CD-Ang-(1-7) alone or CD-Ang-(1-7) associated to atenolol (Two-way ANOVA followed by Bonferroni); *p < 0.05 in comparison basal (Student's t-test for paired observation); † p < 0.05 in comparison to atenolol alone (one-way ANOVA followed by Newman-Keuls).
Statistical analysis
Data were presented as mean ± SE. Differences between before and after were assessed by Student t test for paired observations. Differences among groups were analyzed by one-way ANOVA followed by Newman-Keuls post hoc or two-way ANOVA followed by Bonferroni post hoc. Statistical analysis was performed using the GraphPad Prism Software (version 5.0).
Results
At the beginning of treatment, animals presented similar body weight (averaged of all animals = 322 ± 5 g, n = 40; Fig. 1A ). After 14 weeks of oral treatment, animals of all groups had significantly increased body weight and the values obtained were not different among the groups (averaged of all animals = 391 ± 5 g, n = 40; Fig. 1A ). In addition, only animals treated with the association of Ang-(1-7) and atenolol presented a small but significant decrease in systolic arterial pressure (161 ± 1 mmHg vs 169 ± 1 mmHg, before treatment; n = 5; Paired Student's t-test; data not shown). A decrease in heart rate was observed in animals treated with atenolol alone (286 ± 1 beats/min vs 301 ± 1 beats/min, before; n = 5) or associated to Ang-(1-7) (278 ± 1 beats/min vs 293 ± 1 beats/min, before; n = 5).
As shown in Fig. 1B , on the eighth week of treatment there was no change in fasted glycemia in any of the groups. Although atenolol alone had a trend to increase glucose levels, values were not statistically different.
In order to evaluate lipid profile, at the end of the 14 weeks of treatment, total serum cholesterol, glycerol and triglycerides were measured. As shown in Fig. 1C , CD-Ang-(1-7) or atenolol alone did not alter serum triglycerides. However, animals that received the association of CD-Ang-(1-7) and atenolol presented a ∼60% lower values of total serum cholesterol (13 ± 3 mg/dL; Fig. 1D ) than control animals that received CD alone, vehicle (38 ± 5 mg/dL; Fig. 1D ).
After oral administration of fat load, a hypertriglyceridemia was observed in control (vehicle; 92 ± 33 mg/dL vs 34 ± 3 mg/dL, before; Fig. 2A ) or animals treated with atenolol, with a peak at 210 min (115 ± 17 mg/dL vs 52 ± 6 mg/dL, before; Fig. 2A ). This alteration was not observed in the other groups: CD-Ang-(1-7) alone (52 ± 10 mg/dL vs 35 ± 6 mg/dL, before; Fig. 2A ) or in CD-Ang-(1-7) associated with atenolol (48 ± 8 mg/dL 38 ± 4 mg/dL, before; Fig. 2A) .
Lipolysis was measured by the release of glycerol at baseline and after isoproterenol stimulation or insulin inhibition. As expected, isoproterenol increased glycerol release in all groups (Fig. 2B) . Although the basal lipolysis was similar in all treatments, after isoproterenol stimulation, the association of CD-Ang-(1-7) and atenolol induced a greater lipolysis (120 ± 14 mg/dL; Fig. 2B ) as compared to atenolol alone (82 ± 7 mg/dL; Fig. 2B) . Interestingly, the sensitivity of insulin was not changed by any treatment (Fig. 2C) . Further, the sensitivity of insulin on glucose uptake was measured in adipocytes by radioactivity into the cells, since 2DOG can be transported but not oxidized. We have observed that all treatments did not change glucose uptake or the insulin sensitivity (Fig. 2C) .
Lipoprotein lipase (LPL) is an enzyme that hydrolyzes triglycerides components of lipoproteins providing free fatty acids (FFAs) and monoacylglycerol for being used by tissues. The release 3H-FFAs was quantified by liquid scintillation as an estimative of LPL activity. As shown in Fig. 2D , the LPL activity was not different in all groups studied.
Discussion
The present study showed, for the first time, the metabolic effect of an oral treatment with Ang-(1-7) associated with the ␤-blocker-atenolol. It was observed that CD-Ang-(1-7) in association with atenolol reduced the total cholesterol, improved the oral fat load tolerance and increased the lipolitic response stimulated by isoproterenol without modification of resting glucose or insulin sensitivity in adipocytes of SHR.
Recent studies have shown that an increased activation of ACE2/Ang-1-7/Mas arm of the RAS produces important improvement on lipid and glucose metabolism [2, 8, 13, 19] . Increased circulating Ang-(1-7) in transgenic rats decreases plasma triglyceride and cholesterol improving insulin sensitivity [20] . Corroborating these data it was shown that Mas receptor deficient mice present increased body fat associated to insulin resistance and increased plasma triglycerides and cholesterol levels [21] . A recent study showed that oral treatment with Ang-(1-7) was able to improve metabolism and decreases pro-inflammatory profile in adipose tissue [22] . Our present data further extend these findings by showing that oral treatment with Ang-(1-7) associated with atenolol reduces total cholesterol, improves fat load tolerance and increases the lipolitic response in SHR. The reduced postprandial lipemia induced by Ang-(1-7) treatment may contribute somehow to prevent the development of atherosclerosis. This effect is relevant since the rise in triglyceride-rich lipoproteins after eating is associated with the occurrence of coronary artery disease [9] . It is important to emphasize that the present study is the first to evaluate lipid metabolic response in an arterial hypertension rat model treated with an oral formulation of Ang-(1-7).
Several clinical trials evaluated the lipid metabolic effects of atenolol and ␤-blockers in patients with hypertension and dyslipidemia [6, 24, 28] . In general, it was observed improvement in glucose and lipid metabolism that may reduce the risk of coronary artery disease in high-risk patients with hypertension [6] . On the other hand, several studies did not show an important effect of atenolol on lipid profile [6, 24] , pointing out for the necessity of combined therapies for treating patients with dyslipidemia. Our study shows that the association of Ang-(1-7) with atenolol maybe an important alternative therapy for treating hypertension associated with dyslipidemia.
Although intriguing, the decrease in cholesterol levels in the presence of unchanged fasting glucose and triglycerides concentrations in animals treated with Ang-(1-7) associated with atenolol, could be consequence of the increased uptake of HDL-cholesterol particles from the plasma to the liver by increasing the reverse cholesterol transport [23] . The vasodilator effects of Ang-(1-7) [19] could increase the access of the lipids particles to HDL-cholesterol receptors stimulating the clearance of HDL particles by the liver. In the present study a small decrease in systolic blood pressure was observed only in animals treated with atenolol associated to Ang-(1-7), suggesting that the vasodilatatory actions of Ang-(1-7) potentiated the effects of the ␤-blocker on peripheral resistance, in addition to the decrease in heart rate and cardiac output. Future studies will be necessary to clarify these possibilities.
In summary, the results obtained in the present study show that SHR treated with oral formulation of Ang-(1-7) in combination to ␤-blocker, atenolol, have an improvement of lipid metabolism with a reduction of total plasma cholesterol, improvement of oral fat load tolerance and an increase in the lipolytic response. These results suggest an important effect of Ang-(1-7) as a pharmacological tool for treating lipid alteration in hypertensive patients.
